NCT06225544 - Lumasiran in Hyperoxalaemic Patients on Haemodialysis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

March 1, 2025

Conditions

HaemodialysisChronic Kidney Disease Requiring Chronic DialysisCardiovascular DiseaseCardiovascular Risk FactorHyperoxalemia

Interventions

DRUG

Lumasiran

Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

DRUG

0.9% Sodium Chloride (placebo)

Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

Trial Locations (1)

RECRUITING

Charite Universtiätsmedizin, Berlin